Completed Projects

INSTRUMENT: POR-FESR 2014-2020 – Call: Programma di ricerca e sviluppo per l’integrazione della filiera BIOMED

Project: INCITE

TITLE: INibitori di CDK Innovativi per il Tumore al pancrEas (INCITE) – Innovative CDK Inhibitors for the Treatment of Pancreatic Cancer 

Pancreatic cancer has not yet an adequate treatment and is rated among the most aggressive cancers, with 26.611 new cases in Europe every year, ranking as the 7th leading cause of cancer death in both sexes (over 74% of patients do not survive at 1 year since diagnosis and 95% dies within 5 years).CDK4/6 is an important and actionable target in pancreatic cancer. Furthermore, CDK9 represents a good target in pancreatic cancer as its inhibition can synergize with DNA damaging agents.

ViroStatics established a collaboration with the leading center of the University of Verona, Italy (AOUI, led by prof. Tortora and colleagues), bearing more than 40 years’ experience in the field of pancreatic diseases. Our colleagues have established that ViroStatics’ lead candidate VS2-370 is potent against cell lines from pancreatic cancer, more potent than other drugs currently approved for the treatment of pancreatic cancer or in advanced stage of development. VS2-370 could be used in combination with paclitaxel, GDC0068, LY2090314, SN-38, all treatment options in this setting with which VS2-370 showed synergistic activity in inhibiting tumour growth.

This project successfully concluded in April 2019.

PastedGraphic-4INSTRUMENT: POR FESR 2014-2020 “Innovation Services” – Project CUP G83D1600010002

TITLE: Servizi per l’Innovazione

This project aimed at characterizing the mechanism of action of ViroStatics’ library of compounds with mainly proteomics analysis. These studies have been implemented in collaboration with Porto Conte Ricerche.

Project timeline: Jan 2016-Sep 2016

INSTRUMENT: H2020-SMEInst-2016-2017 – Project “THUNDERPastedGraphic-2

TITLE: Development of the Cyclin-Dependent Kinase Inhibitor VS2-370 to Target HIV-associated Malignancies and to Purge Viral Reservoir.

This project, successfully concluded in July 2017, constituted the feasibility study for the present Phase 2 application.



TITLE: Targeting the HIV-1 Nucleocpsid Protein to fight Antiretroviral Drug Resistance

The goal of the THINPAD project was to discover and develop novel anti-HIV agents targeting the HIV nucleocapsid protein, which is one of the most conserved sequence within HIV  strains and is highly required for HIV replication, being therefore a primary target to overcome antiretroviral drug-resistance.

ViroStatics was one of the 5 partners in the consortium and was supporting the in vitro evaluation of the cytotoxicity profile of the molecules and contributed together with the other SME driving the discovery phase and pre-clinical investigation, favouring the translation of results into innovative applications for health.

Project timeline: Sept 2013-Aug 2016

PastedGraphic-3INSTRUMENT: Contratto di Programma – Project Consorzio Prokemia/ViroStatics

TITLE: Completamento dello sviluppo di un farmaco anti HIV/AIDS

This project aimed at the development of CDK inhibitors (discovery and early preclinical development). During this project ViroStatics has conducted a screening on CDK inhibitors family and was able to identify VS2-370 as lead compound, advancing its preclinical development and performing initial in vitro and in vivo studies.

Project timeline: Jan 2007-Jan 2016

PORINSTRUMENT: POR FESR 2007-2013 – Project CUP E15G13000050007 

TITLE: Progettazione e Studio di Composti “AV-HALT”, Una Nuova Classe di Farmaci con Doppia Attività Antivirale e Immunoprotettrice

During this project we have applied system biology analysis (proteomics and genomics) to ViroStatics’ library of compounds. This has helped elucidating the mechanism of action of the compounds. This work has been performed in collaboration with Porto Conte Ricerche, one of the motors of the Science and Technology Park of Sardinia, active in complementary areas of technology: biomarker discovery, diagnostic systems and biotechnologies applied to nutrition and health.

Project timeline: June 2012-Oct 2014